IQVIA (IQV)
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
$267.77-1.42%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
QuarterlyIQ Insights · IQV
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 13 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $268 IQV trades at 22× p/e, below its 34× p/e peer median. Our $277 fair value sits above the price. It's a high-confidence read. Analysts target $200–$287. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $240.00 | — | — | Analyst | high |
| dcf fcfe | 12M | $279.51 | — | — | Hist. CAGR | high |
| dcf fcff | 12M | $291.57 | — | — | Hist. CAGR | high |
| graham number | 12M | $101.14 | — | — | TTM | high |
| Mgmt guidance |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
$200.00 – $287.00 (median $240.00) · 9 analysts · as of 2026-07-29
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
At today's price you pay about 34% over what the business is worth with no growth; closing that gap needs roughly 11.0 years of the forecast growth to come through. These describe the expectations embedded in the price, not a forecast of the move. Reverse-DCF base: $11.33/sh owner earnings.
Looks cheaper than most peers in the same business.
Richer than its own typical valuation.
Trailing four: 2025-Q2, 2025-Q3, 2026-Q1, 2026-Q2
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| 12M |
| $430.58 |
| 33.9 |
| 12.70 |
| Mgmt |
| high |
| Peer EV/EBITDA | 12M | $262.67 | 18.0 | 19.25 | TTM | high |
| Peer P/FCF | 12M | $420.08 | 34.7 | 12.12 | TTM | high |
| Peer P/E | 12M | $430.51 | 33.9 | 12.70 | TTM | high |
| Peer P/S | 12M | $579.29 | 5.7 | 101.51 | TTM | high |
| PEG | 12M | $933.50 | 73.5 | 12.70 | TTM | high |
| residual income | 12M | $69.12 | — | — | TTM | high |
| Own P/E history | 12M | $246.81 | 19.4 | 12.70 | TTM | high |
| triangulated | 12M | $424.56 | 33.9 | 12.52 | Triangulated | high |
| Mgmt guidance | 3Y | $644.70 | 33.9 | 19.02 | Mgmt(prov.) | medium |
| Peer P/FCF | 3Y | $538.24 | 34.7 | 15.52 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $502.50 | 33.9 | 14.82 | Analyst | medium |
| Peer P/S | 3Y | $645.84 | 5.7 | 113.17 | guidance | medium |
| PEG | 3Y | $1089.62 | 73.5 | 14.82 | Analyst | medium |
| Own P/E history | 3Y | $288.09 | 19.4 | 14.82 | Analyst | medium |
| Mgmt guidance | 5Y | $843.78 | 33.9 | 24.89 | Mgmt(prov.) | high |
| Peer P/FCF | 5Y | $634.96 | 34.7 | 18.31 | Hist. CAGR(prov.) | high |
| Peer P/E | 5Y | $518.43 | 33.9 | 15.29 | Analyst | high |
| Peer P/S | 5Y | $666.31 | 5.7 | 116.76 | guidance | high |
| PEG | 5Y | $1124.15 | 73.5 | 15.29 | Analyst | high |
| Own P/E history | 5Y | $297.22 | 19.4 | 15.29 | Analyst | high |